. European and . Agency, Relevant sources for orphan disease prevalence data, 2014.

E. Council and . Council, on an action in the field of rare diseases, 2009.

. Gatta-g, . Van-der-zwan, C. Jm, and . Pg, Rare cancers are not so rare : the rare cancer burden in Europe, Eur J Cancer, vol.47, pp.2493-2511, 2011.

. Fisher-ra, Statistical Methods for Research Workers, vol.362, 1925.

. Billingham-l, . Malottki-k, and . Steven-n, Research methods to change clinical practice for patients with rare cancers, Lancet Oncol, vol.17, pp.70-80, 2016.

. Stewart-dj and . Kurzrock-r, Cancer : The Road to Amiens, J Clin Oncol, vol.27, pp.328-333, 2009.

C. Ni, . Sullivan-r, and . Dafni-u, A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies : the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS), Ann Oncol, vol.26, pp.1547-1573, 2015.

S. Le, D. Ne, and W. Ds, American Society of Clinical Oncology Statement : A Conceptual Framework to Assess the Value of Cancer Treatment Options, J Clin Oncol, vol.33, pp.2563-2577, 2015.

, Final Summary Report : Integrated Design and Analysis of small population group trials (IDeAl), 2017.

, INSPIRE. Final Report Summary -InSPiRe (Innovative methodology for Small Populations Research, 2017.

. Aserix, Summary Report : Advances in Small Trials dEsign for Regulatory Innovation and eXcellence (ASTERIX), 2017.

. Hilgers-rd, . Roes-k, and . Stallard-n, Directions for new developments on statistical design and analysis of small population group trials, Orphanet Journal of Rare Diseases, vol.11, p.78, 2016.

. Food and . Drug-administation, How FDA Plans to Help Consumers Capitalize on Advances in Science, 2017.

. Casali-pg, . Bruzzi-p, and . Bogaerts-j, Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers : a European consensus position paper, Ann Oncol, vol.26, pp.300-306, 2015.

. Bajard-a, . Chabaud-s, and . Cornu-c, An in silico approach helped to identify the best experimental design, population, and outcome for future randomized clinical trials, J Clin Epidemiol, vol.69, pp.125-161, 2016.

. Pappalardo-f, M. Russo-g, and . Tshinanu-f, silico clinical trials : concepts and early adoptions, 2018.

. Baey-c, . Le, and . Mc, Effect of misspecification of response rates on type I and II errors, in a Phase II Simon design, Eur J Cancer, vol.47, pp.1647-52, 2011.

S. Ratain-mj and . Dj, Optimising the design of phase II oncology trials : The importance of randomisation, Eur J Cancer, vol.45, pp.275-80, 2009.

. Chow-sc and . Chang-m, Adaptive Design Methods in Clinical Trials, vol.374, 2011.

. Gehan-ea, The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent, J Chronic Dis, vol.13, pp.346-53, 1961.

. Fleming-tr, One-Sample Multiple Testing Procedure for Pphase II Clinical Trials, Biometrics, vol.38, pp.143-51, 1982.

. Simon-r, Optimal Two-Stage Designs for Phase II Clinical Trials, Control Clin Trials, vol.10, pp.1-10, 1989.

. Bryant-j and . Day-r, Incorporating Toxicity Considerations into the Design of Two-Stage Phase II Clinical Trials, Biometrics, vol.51, pp.1372-1383, 1995.

M. Sj and S. Dj, Pick the Winner Designs in Phase II Cancer Clinical Trials, J Thorac Oncol, vol.1, pp.5-6, 2006.

. Katz-n, Enriched Enrollment Randomized Withdrawal Trial Designs of Znalgesics : Focus on Methodology, Clin J Pain, vol.25, pp.797-807, 2009.

. Simon-n and . Simon-r, Adaptive enrichment designs for clinical trials, Biostatistics, vol.14, pp.613-625, 2013.

R. T. Johnson-j, Food and Drug Administration requirements for approval of new anticancer drugs, Cancer Treat Rep, vol.69, pp.1155-1164, 1985.

. Saad-e and . Buyse-m, Statistical controversies in clinical research : end points other than overall survival are vital for regulatory approval of anticancer agents, Ann Oncol, vol.27, pp.373-381, 2016.

. European and . Agency, Guideline on Clinical trials in Small Populations, 2006.

R. S. and J. J. Justice-r, Review of oncology and hematology drug product approvals at the US Food and Drug Administration between, J Natl Cancer Inst, vol.102, pp.230-273, 2005.

C. Ni, . Dafni-u, and . Bogaerts-j, ESMO-Magnitude of Clinical Benefit Scale version 1.1, Ann Oncol, vol.28, pp.2340-2366, 2017.

. Bogaerts-j, . Sydes-mr, and . Keat-n, Clinical trial designs for rare diseases : Studies developed and discussed by the International Rare Cancers Initiative, Eur J Cancer, vol.51, pp.271-81, 2015.

S. Sposto-r-et and . Do, A strategic view of randomized trial design in low-incidence paediatric cancer, Stat Med, vol.18, pp.1183-1197, 1999.

B. Le-deley-mc and M. Kv, Taking the long view : How to design a series of Phase III trials to maximize cumulative therapeutic benefit, Clin Trials, vol.9, pp.283-292, 2012.

B. Ma, L. E. Teuff-g, and M. , New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon : a simulation study, Stat Med, vol.35, pp.3245-58, 2016.

T. Lilford-rj, . Jg, and . Braunholtz-d, Clinical trials and rare diseases : a way out of a conundrum, BMJ, vol.311, pp.1621-1625, 1995.

T. Sb, D. Kbg, and . Bruzzi-p, Strategy for randomised clinical trials in rare cancers, BMJ, vol.327, pp.47-56, 2003.

. Billingham-l, . Malottki-k, and . Steven-n, Small sample sizes in clinical trials : a statistician's perspective, Clin Invest, vol.2, pp.655-657, 2012.

T. Smith-c, . Williamson-pr, and . Beresford-mw, Methodology of clinical trials for rare diseases, Best Pract Res Clin Rheumatol, vol.28, pp.247-62, 2014.

, Bayesian clinical trials : no more excuses, Bibliographie 40. GÖNEN M, vol.6, pp.203-204, 2009.

. Nikolakopoulos-s, R. Van-der-tweel-i-et, and . Kc, Dynamic Borrowing through Empirical Power Priors That Control Type I Error, Biometrics, 2017.

. Galwey-nw, Supplementation of a clinical trial by historical control data : is the prospect of dynamic borrowing an illusion, Stat Med, vol.36, pp.899-916, 2017.

I. Jg and C. Mh, Power prior distributions for regression models, Statist Sci, vol.15, pp.46-60, 2000.

. Thall-pf, . Ursino-m, and . Baudouin-v, Bayesian Treatment Comparison Using Parametric Mixture Priors Computed from Elicited Histograms, Stat Methods Med Res, 2017.

L. Biswas-s, L. Dd, and . Jj, Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center, Clin Trials, vol.6, pp.205-221, 2009.

. Bayes-t, An Essay towards solving a Problem in the Doctrine of Chances, Philosoph Trans Roy Soc London, vol.53, pp.370-418, 1763.

. Tsiatis-aa, The asymptotic Joint distribution of the efficient scores test for the proportional hazards model calculated over time, Biometrika, vol.68, pp.311-316, 1981.

. Gilks-w, . Richardson-s, and . Spiegelhalter-d, Markov Chain Monte Carlo in Practice

&. Chapman and . Hall, , vol.504, 1996.

. Geman-s and . Geman-d, Stochastic relaxation, Gibbs distributions, and the Bayesian restoration of images, IEEE Transactions on Pattern Analysis and Machine Intelligence, vol.6, pp.721-741, 1984.

S. Gelfand-ae and . Af, Sampling-Based Approaches to Calculating Marginal Densities, J Am Stat Assoc, vol.85, pp.398-409, 1990.

. Metropolis-n, . Rosenbluth-a, and . Rosenbluth-m, Equations of State Calculations by Fast Computing Machines, J Chem Phys, vol.21, pp.1087-1092, 1953.

. Hastings-wk, Monte Carlo sampling methods using Markov chains and their applications, Biometrika, vol.57, pp.97-109, 1970.

J. Geweke, Evaluating the Accuracy of Sampling-Based Approaches to the Calculation of Posterior Moments, Bayesian Statistics 4, pp.169-193, 1992.

W. Heidelberger-p and . Pd, Simulation run length control in the presence of an initial transient, Op Research, vol.31, pp.1109-1144, 1983.

. Bernardo-jm, J. O. Berger, and D. Ap, Bayesian Statistics, vol.4, 1991.

R. Gelman-a and . Db, Inference from Iterative Simulation Using Multiple Sequences, Statist Sci, vol.7, pp.457-511, 1992.

. Brooks-sp, General Methods for Monitoring Convergence of Iterative Simulation, J Comput Graph Statist, vol.7, pp.434-455, 1998.

. Berry-da, Bayesian clinical trials, Nat Rev Drug Discov, vol.5, pp.27-36, 2006.

L. Jj and C. Ct, Bayesian clinical trials in action, Stat Med, vol.31, pp.2955-72, 2012.

W. Westover-mb, . Kd, and . Bianchi-mt, Significance testing as perverse probabilistic reasoning, BMC Med, vol.9, p.20, 2011.

. Gsponer-t, . Gerber-f, and . Bornkamp-b, A practical guide to Bayesian group sequential designs, Pharm Stat, vol.13, pp.71-80, 2014.

C. Saville-br, A. Jt, and . Gd, The utility of Bayesian predictive probabilities for interim monitoring of clinical trials, Clin Trials, vol.11, pp.485-493, 2014.

. Thomas-a, . Spiegelhalter-d, B. Gilks-w-;-de, D. Jm, . Ap et al., BUGS : a program to perform Bayesian inference using Gibbs sampling, Bayesian Statistics 4. Sous la dir, pp.837-842, 1992.

S. Parmar-mkb, . Dj, and . Freedman-ls, The CHART trials : Bayesian design and monitoring in practice, Stat Med, vol.13, pp.1297-1312, 1994.

U. Parmar-mkb, . Rs, and . Simon-r, Assessing Whether to Perform a Confirmatory Randomized Clinical Trial, J Natl Cancer Inst, vol.88, pp.1645-51, 1996.

M. Spiegelhalter-dj, . Jp, and . Jones-dr, Bayesian methods in health technology assessment : a review, Health Technol Assess, vol.4, pp.1-130, 2000.

L. Lesaffre-e and . Ab, Bibliographie 67, Bayesian Biostatistics, vol.534, 2012.

R. Chaloner-k-et and . Fs, Quantifying and documenting prior beliefs in clinical trials, Stat Med, vol.20, pp.581-600, 2001.

. Spiegelhalter-dj, M. Abrams-kr, and . Jp, Bayesian Approaches to Clinical Trials and Health-Care Evaluation, vol.408, 2004.

O. , B. Ce, and . Daneshkhah-a, Uncertain Judgements : Eliciting Experts' Probabilities, vol.321, 2006.

. Hiance-a, . Chevret-s, and . Lévy-v, A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial, J Clin Epidemiol, vol.62, pp.431-437, 2009.

J. Sr, T. Ga, and . Hawker-ga, A valid and reliable belief elicitation method for Bayesian priors, J Clin Epidemiol, vol.63, pp.370-383, 2010.

. Albert-i and G. Donnet-s, Combining Expert Opinions in Prior Elicitation, Bayesian Anal, vol.7, pp.503-532, 2012.

. Kinnersley-n and . Day-s, Structured approach to the elicitation of expert beliefs for a Bayesian-designed clinical trial : a case study, Pharm Stat, vol.12, pp.104-117, 2013.

. Moatti-m, . Zohar-s, and . Facon-y, Modeling of experts divergent prior beliefs for a sequential phase III clinical trial, Clin Trials, vol.10, pp.505-514, 2013.

. Pibouleau-l, An internet-based method to elicit experts' beliefs for Bayesian priors : a case study in intracranial stent evaluation, Int J Technol Assess Health Care, vol.30, pp.446-453, 2014.

. Hampson-lv, J. Whitehead, and . Eleftheriou-d, Elicitation of Expert Prior Opinion : Application to the MYPAN Trial in Childhood Polyarteritis Nodosa, Plos One, vol.10, p.120981, 2015.

P. Sj, The combination of randomized and historical controls in clinical trials, J Chronic Dis, vol.29, pp.175-88, 1976.

. Food and . Administration, Guidance for industry and FDA staff : Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials, 2010.

. Wadsworth-i and . Hampson-l, Extrapolation of efficacy and other data to support the development of new medicines for children : A systematic review of methods, Stat Methods Med Res, vol.27, pp.398-413, 2018.

I. Jg, C. Mh, and . Chu-h, Bayesian methods in clinical trials : a Bayesian analysis of ECOG trials E1684 and E1690, BMC Med Res Methodol, vol.12, p.183, 2012.

. Neuenschwander-b, S. Branson-m-et, and . Dj, A note on the power prior, Stat Med, vol.28, pp.3562-3566, 2009.

. Hobbs, C. Bp, . Bp, and . Mandrekar-s, Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials, Biometrics, vol.67, pp.1047-56, 2011.

. Hobbs, S. Bp, C. Dj, and . Bp, Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models, Bayesian Anal, vol.7, pp.639-674, 2012.

M. Ta, H. Bp, and L. Tc, Semiparametric Bayesian commensurate survival model for post-market medical device surveillance with non-exchangeable historical data, Biometrics, vol.70, pp.185-91, 2014.

K. Kaizer-am, . Js, and . Hobbs-bp, Bayesian Hierarchical Modeling based on Multisource Exchangeability. Biostatistics, vol.19, pp.169-184, 2018.

. Campbell-g, Bayesian methods in clinical trials with applications to medical devices, Communications for Statistical Applications and Methods, vol.24, pp.561-581, 2017.

C. Neuenschwander-b and . Branson-m, Summarizing historical information on controls in clinical trials, Clin Trials, vol.7, pp.5-18, 2010.

. Bibliographie-89, N. Gsteiger-s, and . Mercier-f, Using historical control information for the design and analysis of clinical trials with overdispersed count data, Stat Med, vol.32, pp.3609-3631, 2013.

. Schmidli-h, . Gsteiger-s, and . Roychoudhury-s, Robust meta-analytic-predictive priors in clinical trials with historical control information, Biometrics, vol.70, pp.1023-1055, 2014.

. Mutsvari-t, . Tytgat-d, and . Walley-r, Addressing potential prior-data conflict when using informative priors in proof-of-concept studies, Pharm Stat, vol.15, pp.28-36, 2016.

. Gelman-a, Objections to Bayesian statistics, Bayesian Anal, vol.3, pp.445-449, 2008.

L. A. Moyé, Bayesians in clinical trials : Asleep at the switch, Stat Med, vol.27, pp.469-82, 2008.

L. Wasserstein-rl and . Na, The ASA's Statement on p-Values : Context, Process, and Purpose, Am Statist, vol.70, pp.129-133, 2016.

. Hughes-md, Reporting Bayesian analyses of clinical trials, Stat Med, vol.12, pp.1651-1663, 1993.

. Goligher-e, . Tomlinson-g, and . Hajage-d, Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical Trial, JAMA, 2018.

. Berry-d, Interim analyses in clinical trials : Classical vs. Bayesian approaches, Stat Med, vol.4, pp.521-527, 1985.

C. Bp, K. Chaloner, and . Church-t, Bayesian approaches for monitoring clinical trials with an application to toxoplasmic encephalitis prophylaxis, The Statistician, vol.42, pp.355-367, 1993.

G. Sl, L. C. , and B. Da, Stopping a clinical trial early : Frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer, Stat Med, vol.13, pp.1313-1340, 1994.

S. Freedman-ls, . Dj, and . Parmar-mk, The What, Why and How of Bayesian clinical trials monitoring, Stat Med, vol.13, pp.1371-1383, 1994.

. Heitjan-df, Bayesian interim analysis of phase II cancer clinical trials, Stat Med, vol.16, pp.1791-802, 1997.

. Rosner-gl, Bayesian Monitoring of Clinical Trials with Failure-Time Endpoints, Biometrics, vol.61, pp.239-245, 2005.

J. Ve and . Cook-jd, Bayesian Design of Single-arm Phase II Clinical Trials with Continuous Monitoring, Clin Trials, vol.6, pp.217-243, 2009.

A. D. Fayers-pm and . Parmar-mkb, Tutorial in biostatistics Bayesian data monitoring in clinical trials, Stat Med, vol.16, pp.1413-1443, 1997.

J. C. Lunn-d and . Best-n, The BUGS Book : A Practical Introduction to Bayesian Analysis, vol.399, 2012.

. European and . Agency, Concept paper on extrapolation of efficacy and safety in medicine development, 2013.

. Viele-k, . Berry-s, and . Neuenschwander-b, Use of historical control data for assessing treatment effects in clinical trials, Pharm Stat, vol.13, pp.41-54, 2014.

. Hogarth-rm, Cognitive Processes and the Assessment of Subjective Probability Distributions, J Am Statist Assoc, vol.70, pp.271-289, 1975.

L. E. Brard-c, L. E. Teuff-g, and . Mc, Bayesian survival analysis in clinical trials : What methods are used in practice ?, Clin Trials, vol.14, pp.78-87, 2017.

I. Jg, C. Mh, and . Sinha-d, Bayesian Survival Analysis, vol.480, 2001.

. Anderson-h, B. Lund, and . Bach-f, Single-Agent Activity of Weekly Gemcitabine in Advanced Non-Small-Cell Lung Cancer : A Phase II Study, J Clin Oncol, vol.12, pp.1821-1826, 1994.

. Bibliographie,

L. Sh, A. Dm, and N. Me, The Impact of Radiation on Early Breast Carcinoma Survival : A Bayesian analysis, Cancer, vol.78, pp.1035-1077, 1996.

. Ménard-s, . Valagussa-p, and . Pilotti-s, Response to Cyclophosphamide, Methotrexate, and Fluorouracil in Lymph Node-Positive Breast Cancer According to HER2 Overexpression and Other Tumor Biologic Variables, J Clin Oncol, vol.19, pp.329-364, 2001.

T. Estey-eh, G. Pf, and . Fj, Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome : comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside, Blood, vol.99, pp.4343-4352, 2002.

. Gennari-a, . Amadori-d, and . De-lena-m, Lack of Benefit of Maintenance Paclitaxel in First-Line Chemotherapy in Metastatic Breast Cancer, J Clin Oncol, vol.24, pp.3912-3920, 2006.

W. Maki-rg, P. Jk, and . Sr, Randomized Phase II Study of Gemcitabine and Docetaxel Compared with Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas : Results of Sarcoma Alliance for Research Through Collaboration Study 002, J Clin Oncol, vol.25, pp.2755-2763, 2007.

G. Chamberlain-mc and . Mj, Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas, Cancer, vol.113, pp.2146-51, 2008.

. Miksad-ra, M. Gönen, and L. Tj, Interpreting Trial Results in Light of Conflicting Evidence : A Bayesian Analysis of Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer, J Clin Oncol, vol.27, pp.2245-52, 2009.

M. Hb, B. Da, and C. Ct, Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer, N Engl J Med, vol.360, pp.2055-65, 2009.

T. Norman-ph, P. Pf, and . Rv, A Possible Association Between Aprotinin and Improved Survival After Radical Surgery for Mesothelioma, Cancer, vol.115, pp.833-874, 2009.

. Pecorelli-s, . Favalli-g, and . Gadducci-a, Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy : Final Results of the After-6 Protocol 1, J Clin Oncol, vol.27, pp.4642-4648, 2009.

G. De-lima-m and T. Pf, Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome : a dose and schedule finding study, Cancer, vol.116, pp.5420-5431, 2010.

L. Lu-c, . Jj, and . Komaki-r, Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer : a randomized phase III trial, J Natl Cancer Inst, vol.102, pp.859-65, 2010.

W. Dj, C. Pappone, and . Neuzil-p, Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation : a randomized controlled trial, JAMA, vol.303, pp.333-373, 2010.

G. , T. Fp, and B. Nb, Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome, J Clin Oncol, vol.30, pp.2204-2214, 2012.

. Sharma-m, H. Khan, and T. Pf, A Randomized Phase II Trial of a Preparative Regimen of Bortezomib, High Dose Melphalan, Arsenic Trioxide and Ascorbic Acid, Cancer, vol.118, pp.2507-2522, 2012.

C. Shulman-ln, B. Ct, and . Da, Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes : Cancer and Leukemia Group B 40101, J Clin Oncol, vol.30, pp.4071-4077, 2012.

C. Ab, W. Sj, and A. Pb, Biventricular pacing for atrioventricular block and systolic dysfunction, N Engl J Med, vol.368, pp.1585-93, 2013.

W. Hensley-ml, . Jk, and . Maki-rg, Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma : results of a phase 2 trial (SARC 005), Cancer, vol.119, pp.1555-61, 2013.

M. Von-minckwitz-g and . Schneeweiss-a, German adjuvant intergroup node-positive study : a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer, J Clin Oncol, vol.31, pp.3531-3540, 2013.

M. Rk, M. Gl, and Q. , Percutaneous vesicoamniotic shunting versus conservative management for fetal lower urinary tract obstruction (PLUTO) : a randomised trial, Lancet, vol.382, pp.1496-1506, 2013.

. Ueno-h, T. Ioka, and . Ikeda-m, Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study, J Clin Oncol, vol.31, pp.1640-1648, 2013.

. Motzer-rj, C. H. Barrios, and K. Tm, Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma, J Clin Oncol, vol.32, pp.2765-2772, 2014.

O. Kanakry-cg, . Pv, and . Furlong-t, Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning, J Clin Oncol, vol.32, pp.3497-505, 2014.

P. M. Le-deley-mc and L. I. , Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma : results of the randomized noninferiority Euro-EWING99-R1 trial, J Clin Oncol, vol.32, pp.2440-2448, 2014.

. Satouchi-m, Y. Kotani, and . Shibata-t, Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer : JCOG 0509, J Clin Oncol, vol.32, pp.1262-1270, 2014.

. Shulman, B. Ln, C. Da, and . Ct, Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes : CALGB 40101 (Alliance), J Clin Oncol, vol.32, pp.2311-2317, 2014.

. Stephenson-jj, J. Nemunaitis, and J. Aa, Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer, Lung Cancer, vol.83, pp.219-242, 2014.

C. Gelman-a, S. Jb, and . Hs, Bayesian Data Analysis

&. Chapman and . Hall, , vol.675, 2013.

S. Thall-pf and . Hg, Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials, Stat Med, vol.17, pp.1563-80, 1998.

. Brophy-jm and . Joseph-l, Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes, JAMA, vol.273, pp.871-876, 1995.

. Schwarz-g, Estimating the Dimension of a Model, Ann Stat, vol.6, pp.461-464, 1978.

H. J. Sung-l and G. Ml, Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study, J Clin Epidemiol, vol.58, pp.261-269, 2005.

A. D. , Bayesian statistics in medicine : a 25 year review, Stat Med, vol.25, pp.3589-631, 2006.

. Pibouleau-l, Bayesian statistical method was underused despite its advantages in the assessment of implantable medical devices, J Clin Epidemiol, vol.64, pp.270-279, 2011.

C. S. , Bayesian adaptive clinical trials : a dream for statisticians only, Stat Med, vol.31, pp.1002-1015, 2012.

. Bibliographie,

. Saunders-m, S. Dische, and . Barrett-a, Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer : mature data from the randomised multicentre trial, Radiother Oncol, vol.52, pp.137-185, 1999.

. Berry-da, Bayesian methods in phase III trials, Drug information journal, vol.25, pp.345-368, 1991.

. Berry-da, Introduction to Bayesian methods III : use and interpretation of Bayesian tools in design and analysis, Clin Trials, vol.2, pp.364-378, 2005.

. Greenhouse-jb and . Seltman-h, Using prior distributions to synthesize historical evidence : comments on the Goodman-Sladky case study of IVIg in Guillain-Barré syndrome, Clin Trials, vol.2, pp.311-319, 2005.

. Parmar-mkb, M. Sydes-mr, and . Tp, How do you design randomised trials for smaller populations ? A framework, BMC Med, vol.14, p.183, 2016.

L. I. Jx, C. Wc, and S. Ja, Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information, J Biopharm Stat, vol.26, pp.1056-1066, 2016.

. Gravestock-i, C. Held-l-et, and . Consortium, Adaptive power priors with empirical Bayes for clinical trials, Pharm Stat, vol.16, pp.349-360, 2017.

. Vail-d, . Macewen-e, and . Kurzman-i, Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog : a randomized multi-institutional clinical trial, Clin Cancer Res, vol.1, pp.1165-70, 1995.

K. Id, M. Eg, and . Rosenthal-rc, Adjuvant therapy for osteosarcoma in dogs : results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin, Clin Cancer Res, vol.1, pp.1595-601, 1995.

. Bibliographie,

P. A. Meyers, . Schwartz-cl, and . Krailo-m, A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate, J Clin Oncol, vol.23, pp.2004-2015, 2005.

P. A. Meyers, K. Schwartz-cl, and . Md, The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival -A Report From the Children's Oncology Group, J Clin Oncol, vol.26, pp.633-641, 2008.

K. Chou-aj, K. Es, and . Md, Addition of Muramyl Tripeptide to Chemotherapy for Patients with Newly Diagnosed Metastatic Osteosarcoma : a Report from the Children's Oncology Group, Cancer, vol.115, pp.5339-5387, 2009.

. Kager-l, . Pötschger-u, and . Bielack-s, Review of mifamurtide in the treatment of patients with osteosarcoma, Ther Clin Risk Manag, vol.6, pp.279-286, 2010.

L. E. Piperno-neumann-s and R. Deley-mc, Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006) : a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, vol.17, pp.1070-1080, 2016.

. Royston-p and . Parmar-mkb, Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects, Stat Med, vol.21, pp.2175-97, 2002.

H. Akaike, A new look at the statistical model identification, IEEE Transactions on Automatic Control, vol.19, pp.716-723, 1974.

. Schoenfeld-da, Sample-Size Formula for the Proportional-Hazards Regression Model, Biometrics, vol.39, pp.499-503, 1983.

R. Core-team, R. Foundation, and . Statistical-computing, R : A Language and Environment for Statistical Computing, 2016.

A. J. , LearnBayes : Functions for Learning Bayesian Inference, 2014.

M. Ad, . Quinn-km, P. J. Hee, and . Mcmcpack, Markov Chain Monte Carlo in R, J Statist Soft, vol.42, p.42, 2011.

. Cuffe-rl, The inclusion of historical control data may reduce the power of a confirmatory study, Stat Med, vol.30, pp.1329-1367, 2011.

D. P. Dejardin-d and . Warne-c, Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment : A case study and discussion of practical implementation aspects, Pharm Stat, vol.17, pp.169-181, 2018.

J. Van-rosmalen and D. D. Van-norden-y, Including historical data in the analysis of clinical trials : Is it worth the effort ?, Stat Methods Med Res, vol.27, pp.3167-3182, 2018.

A. P. Wijeysundera-d and . Hux-j, Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials, J Clin Epidemiol, vol.62, pp.13-21, 2009.

. Quintana-m, L. Viele-k, and . Rj, Bayesian Analysis : Using Prior Information to Interpret the Results of Clinical Trials, JAMA, vol.318, pp.1605-1606, 2017.

. Whelan-j, . Le-deley, and D. Mc, High dose chemotherapy with busulfan-melphalan and blood autologous stem cell rescue compared to standard chemotherapy in localized high-risk Ewing sarcoma : Results of R2Loc randomization in Euro-E.W.I.N.G.99 and Ewing2008 controlled trials, J Clin Oncol, 2018.

. Grill-j, . Massimino-m, and . Bouffet-e, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma, J Clin Oncol, vol.II, pp.951-958, 2018.

. The, . Lung, . Trial, and . Group,

, Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer, N Engl J Med, vol.350, pp.351-360, 2004.

. Moher-d, . Schulz-kf, and . Altman-dg, The CONSORT statement : revised recommendations for improving the quality of reports of parallel-group randomised trials, Lancet, vol.357, pp.1191-1195, 2001.

. Neelon-b-et-o'malley-a, The Use of Power Prior Distributions for Incorporating Historical Data into a Bayesian Analysis. Department of Health Care Policy, Harvard Medical School, 2009.

. Rietbergen-c, . Klugkist-i, and . Janssen-kjm, Incorporation of historical data in the analysis of randomized therapeutic trials, Contemp Clin Trials, vol.32, pp.845-55, 2011.